Sponsors (7)
The bill shifts regulatory reliance toward validated non-animal testing methods and increases transparency and animal-welfare safeguards, at the cost of added compliance, reporting burdens, potential penalties, and risks of approval delays or higher short-term costs for firms that still depend on animal data.
Manufacturers and regulators: Can rely on validated non-animal safety testing methods, reducing animal use and bringing approvals more in line with modern science.
Small businesses and manufacturers: Agencies may remove outdated animal-data requirements, potentially lowering long-term testing costs and regulatory burden.
Manufacturers: When animal tests remain necessary, they must minimize the number of animals used and reduce pain, improving animal welfare in required testing.
Small businesses and manufacturers that currently rely on animal testing: May face compliance costs or lost product approvals if validated non-animal methods are not yet practicable or accepted.
Patients (especially those with chronic conditions) and manufacturers: Could experience slower product approvals or extra testing if agencies and industry disagree about whether non-animal methods are adequate.
Small businesses and manufacturers: New public reporting requirements may increase administrative burdens and raise disclosure concerns when preparing regulatory submissions.
Based on analysis of 2 sections of legislative text.
Prohibits submitting animal-test data to CPSC, USDA, EPA, and FDA when an accepted non-animal method exists, sets exceptions, penalties, agency guidance, and reporting.
Introduced December 11, 2025 by Jared Moskowitz · Last progress December 11, 2025
Makes it illegal to submit animal-test-derived data to four federal agencies (CPSC, USDA, EPA, FDA) when the agency has identified an acceptable non-animal test method or has waived the animal-test requirement. It creates limited exceptions, requires minimization of animal use and suffering where animal tests nonetheless occur, authorizes agencies to refuse tainted data and levy civil penalties (up to $10,000 per violation), and requires agencies to issue guidance, revise rules, and publish annual progress reports on testing and waivers.